Cytokinetics, Inc. (Nasdaq: CYTK) to Ring The Nasdaq Stock Market Closing Bell
30 April 2016 - 12:00AM
What: Cytokinetics, Inc.
(Nasdaq:CYTK), a late-stage biopharmaceutical company focused on
discovering, developing and commercializing first-in-class muscle
activators as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining, will
visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Robert Blum,
President and Chief Executive Officer, will ring the
Closing Bell.
Where:Nasdaq MarketSite – 4 Times
Square – 43rd & Broadway – Broadcast Studio
When:Monday, May 2, 2016 – 3:45
p.m. to 4:00 p.m. ET
Cytokinetics Media Contact:Diane
Weiser(650) 624-3060investor@cytokinetics.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line
(Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811
Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia
features such as exclusive content, photo postings, status updates
and video of bell ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit
our Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please
visit our YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos,
please visit our Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the
Nasdaq Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution
photograph of the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About CytokineticsCytokinetics is
a late-stage biopharmaceutical company focused on discovering,
developing and commercializing first-in-class muscle activators as
potential treatments for debilitating diseases in which muscle
performance is compromised and/or declining. As a leader in muscle
biology and the mechanics of muscle performance, the company is
developing small molecule drug candidates specifically engineered
to increase muscle function and contractility. Cytokinetics’ lead
drug candidate is tirasemtiv, a fast skeletal muscle activator, for
the potential treatment of ALS. Tirasemtiv has been granted orphan
drug designation and fast track status by the U.S. Food and Drug
Administration and orphan medicinal product designation by the
European Medicines Agency for the potential treatment of ALS.
Cytokinetics retains the right to develop and commercialize
tirasemtiv. Cytokinetics is collaborating with Amgen Inc. to
develop omecamtiv mecarbil, a novel cardiac muscle activator, for
the potential treatment of heart failure. Cytokinetics is
collaborating with Astellas Pharma Inc. to develop CK-2127107, a
fast skeletal muscle activator, for the potential treatment of
spinal muscular atrophy. Amgen holds an exclusive license worldwide
to develop and commercialize omecamtiv mecarbil and Astellas holds
an exclusive license worldwide to develop and commercialize
CK-2127107. Both licenses are subject to Cytokinetics’ specified
development and commercialization participation rights. For
additional information about Cytokinetics, visit
www.cytokinetics.com.
About NasdaqNasdaq (Nasdaq:NDAQ)
is a leading provider of trading, clearing, exchange technology,
listing, information and public company services across six
continents. Through its diverse portfolio of solutions, Nasdaq
enables customers to plan, optimize and execute their business
vision with confidence, using proven technologies that provide
transparency and insight for navigating today's global capital
markets. As the creator of the world's first electronic stock
market, its technology powers more than 70 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions.
Nasdaq is home to more than 3,700 listed companies with a market
value of approximately $9.3 trillion and nearly 17,000 corporate
clients. To learn more, visit: nasdaq.com/ambition or
business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Sep 2023 to Sep 2024